No profile data available.
Neuronetics, Inc. (STIM) is a healthcare company in the targeted healthcare equipment industry, based in Malvern, United States, with about 658 full-time employees.
It reported revenue of $74.89 million for fiscal year 2024, up 5.0% from fiscal year 2023, and net income of -$43.71 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $37.30 million, up 101.3% from a year before. Its largest business segment, Clinic Services Market, brought in 58% of segment revenue in fiscal year 2025; United States was the largest region with 98%. Its market capitalization was $162.30 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Neuronetics reported $74.89 million in revenue for fiscal year 2024, up 5.0% from $71.35 million in fiscal year 2023. In Q3 2025 revenue was $37.30 million.
Clinic Services Market, with $86.98 million or 58% of segment revenue in fiscal year 2025. Next: Medical Device (42%).
United States: 98% of revenue by region in fiscal year 2025, followed by International (2%).
$162.30 million as of October 9, 2026.
Listed companies of a similar size in the same industry (targeted healthcare equipment) include RxSight, Inc. (RXST), Deltex Medical Group plc (DTXMF), Inogen, Inc. (INGN), Solana Co (HSDT).